City Therapeutics key facts
as of Oct 2026- Operator of a biotechnology company intended to develop innovative, precise, and effective treatments for a wide range of diseases.
- City Therapeutics is valued at approximately $285.5M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $139.5M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($135.0M) in Oct 2024.
- Notable investors include Fidelity Management & Research Company, ARCH Venture Partners, The Invus Group, Rock Springs Capital, Slate Path Capital — 8 tracked in total.
- 2 institutional filers report fund marks on City Therapeutics across 2 filings.
- Status: Privately Held (backing).
Nothing comparable since the round — shown at its Series A, Oct 2024 ($285.5M post-money).
- ·Watch City Therapeutics: the Monday email on marks, rounds and moves
Institutional fund marks on City Therapeutics
2 filers · latest Jul 20262 SEC-registered funds reported 2 fair-value marks on City Therapeutics between May 2026 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
City Therapeutics funding rounds
1 roundsCity Therapeutics valuation
City Therapeutics is valued at approximately $285 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its Series A in Oct 2024, at a $285 million post-money valuation.
Recent activity
In the last 90 days, City Therapeutics's record added 1 institutional fund mark (latest period Jul 2026).
How much has City Therapeutics raised?
City Therapeutics has raised $140 million across 1 recorded round since 2024. The largest was a $135 million Series A in Oct 2024.
Institutional holders and vehicles
2 SEC-registered funds reported 2 fair-value marks on City Therapeutics between May 2026 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
City Therapeutics investors
8 investors are on record for City Therapeutics, including Fidelity Management & Research Company, ARCH Venture Partners, The Invus Group and Rock Springs Capital. The Series A in Oct 2024 drew 7 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Mythic Therapeutics ($293 million), Convergent Therapeutics ($280 million) and Ensoma ($280 million).
About City Therapeutics
Operator of a biotechnology company intended to develop innovative, precise, and effective treatments for a wide range of diseases. The company focuses on creating medicines that use RNAi technology to silence harmful gene expression by targeting and degrading messenger RNA (mRNA), enabling healthcare professionals to offer more targeted and more effective treatment options for their patients, especially in disease areas with limited treatment.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Employees
- 47
- Website
- citytx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.